Áõ»óÀÌ ÀÖ´Â °ñÀüÀÌ Àü¸³¼±¾ÏÀÇ Ä¡·á¿¡ ÀÖ¾î¼ Strontium-89 Ä¡·áÀÇ Ãʱâ°æÇè
Early Experience of Strontium-89 Therapy for Pain Palliation in the Patients with Symptomatic Metastatic Prostate Cancer
À̵¿Çö, ÃÖ¿ë¼·, ÃÖÀº¼±, Á¤º´Ã¶,
¼Ò¼Ó »ó¼¼Á¤º¸
À̵¿Çö ( )
¿¬¼¼´ëÇб³
ÃÖ¿ë¼· ( )
¿¬¼¼´ëÇб³
ÃÖÀº¼± ( )
¿¬¼¼´ëÇб³
Á¤º´Ã¶ ( )
¿¬¼¼´ëÇб³
KMID : 0358319960370090974
Abstract
In patients with prostatic adenocarcinoma with bony metastasis, pain pallition is an important point in improving their life quality. It is a known fact that local external irradiation is an effective treatment modality for metastatic bone pain.
Because
bony metastasis often affects multiple sites in prostatic addenocarcinloma, hemibody irradiation is often necessary. But it has various complications. Strontium-89 was administered in 6 patients with prostatic adenocarcinloma with symptomatic
multiple
bony multiple bony metastasis whose pain was not controlled with local external irradiation or antiandrogen therapy. In 2 of 6 patients, pain disappeared and in other 2 of 6 patients, pain decreased to 20% of pretreatment level. Hematologic
adverse
effect did not appear in any patient. Along with decreasing pain, need of analgesics decreased and life quality of the patiens improveed. However, the PSA level of the patients did not change.
Strontium-89 treatment for patiens with prostatic adenocarcinoma with symptomatic bony metastasis is a valuable treatment modality in improving life quality of the patiens and timesaving when compared with other treatment modalities. However
there
are
some unsolved questions in Strontium-89 treatment such as when to start the treatment and its indications. A prospective study should be designed including more cases.
Å°¿öµå
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸